Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-30-253-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio10.05
Quick Ratio10.05
Price-To-Earnings
Trailing P/E Ratio-5.01
Forward P/E Ratio-5.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.36 million
Price / Sales32.06
Cash FlowN/A
Price / CashN/A
Book Value$2.79 per share
Price / Book7.80
Profitability
EPS (Most Recent Fiscal Year)($4.29)
Net Income$-82,610,000.00
Net Margins-530.70%
Return on Equity-91.14%
Return on Assets-28.35%
Miscellaneous
Employees51
Outstanding Shares22,630,000
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
How were Merus' earnings last quarter?
Merus NV (NASDAQ:MRUS) announced its quarterly earnings data on Thursday, April, 26th. The biotechnology company reported ($0.86) EPS for the quarter. The biotechnology company had revenue of $4.49 million for the quarter. Merus had a negative net margin of 530.70% and a negative return on equity of 91.14%. View Merus' Earnings History.
When is Merus' next earnings date?
What price target have analysts set for MRUS?
3 equities research analysts have issued 12 month price objectives for Merus' shares. Their forecasts range from $28.00 to $32.00. On average, they expect Merus' stock price to reach $30.00 in the next twelve months. View Analyst Ratings for Merus.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Aimmune Therapeutics (AIMT), AnaptysBio (ANAB), PTC Therapeutics (PTCT), Myokardia (MYOK), Mallinckrodt (MNK), Biohaven Pharmaceutical (BHVN), Zogenix (ZGNX), TherapeuticsMD (TXMD), Cambrex (CBM), Pacira Pharmaceuticals (PCRX), G1 Therapeutics (GTHX), ARMO Biosciences (ARMO), Innoviva (INVA), Wave Life Sciences (WVE) and Myovant Sciences (MYOV).
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg Ph.D., Co-Founder, CEO & Exec. Director (Age 60)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Mr. John J. Crowley, CFO & Exec. VP (Age 44)
- Mr. John de Kruif Ph.D., CTO & Sr. VP
- Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 51)
When did Merus IPO?
(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Has Merus been receiving favorable news coverage?
News stories about MRUS stock have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merus earned a news impact score of 0.20 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Merus' major shareholders?
Merus' stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (10.69%), Sofinnova Ventures Inc (8.67%), Rock Springs Capital Management LP (0.77%), Iguana Healthcare Management LLC (0.33%), Stanley Laman Group Ltd. (0.24%) and Millennium Management LLC (0.06%). View Institutional Ownership Trends for Merus.
Which institutional investors are selling Merus stock?
MRUS stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP and Iguana Healthcare Management LLC. View Insider Buying and Selling for Merus.
Which institutional investors are buying Merus stock?
MRUS stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Sofinnova Ventures Inc, Stanley Laman Group Ltd. and Millennium Management LLC. View Insider Buying and Selling for Merus.
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $21.76.
How big of a company is Merus?
Merus has a market capitalization of $466.75 million and generates $15.36 million in revenue each year. The biotechnology company earns $-82,610,000.00 in net income (profit) each year or ($4.29) on an earnings per share basis. Merus employs 51 workers across the globe.
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
